Overview

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Gedeon Richter Plc.
Treatments:
Teriparatide